Social Anxiety Disorder (SAD) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Social anxiety disorder (SAD) is characterised by persistent anxiety when exposed to observation or scrutiny by others and fear of acting in a way that will be embarrassing or humiliating. SAD is divided into generalised and non-generalized subtypes. In the former, most social situations are feared. In the latter, either a single or several social or performance conditions are stressed. The impact of social anxiety is widespread, affecting functioning in various domains of life and lowering general mood and wellbeing.

·       A lifetime prevalence of SAD of up to 12% has been reported in the US, and 12-month prevalence rates of .8% have been reported across Europe and 0.2% in China.

·       Younger individuals are disproportionately affected by social anxiety, with prevalence rates at around 10% by the end of adolescence, with 90% of cases occurring by age 23.

The competitive landscape of Social Anxiety Disorder (SAD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Social Anxiety Disorder (SAD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Social Anxiety Disorder (SAD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Social Anxiety Disorder (SAD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          PH94B  VistaGen Therapeutics, Inc.       Phase 3

2          BHV-0223         Biohaven Pharmaceuticals, Inc. Phase 3

3          JNJ-42165279   Janssen Research & Development, LLC Phase 2

4          GW876008       GlaxoSmithKline            Phase 2

5          atomoxetine      Eli Lilly and Company    Phase 3

6          Pegasys-VR      Virtually Better, Inc.       Phase 2

7          Cannabidiol (CBD) Oil Capsules Tilray    Phase 3

8          VQW-765         Vanda Pharmaceuticals Phase 2

9          SPD503 (extended-release Guanfacine hydrochloride)    Takeda            Phase 2

10        levetiracetam    UCB Pharma    Phase 2

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more